Preliminary findings of a Brazilian public lung cancer screening program in Brazil
<bold>INTRODUCTION:</bold> Low dose computed tomography (LDCT) screening is a proven strategy for reducing deaths from lung cancer in high risk populations. Additionally, CT screening in combination with lung function testing can identify other pulmonary diseases. <bold>OBJECTIVE:</bold> To assess the feasibility and findings of a LDCT and lung function screening program in a public Hospital in Brazil. <bold>METHODS:</bold> The program was implemented in Botucatu, São Paulo, Brazil and the study aims at including 1000 individuals. Inclusion criteria included: age 45-75 years, smoking history of 30 years pack or former smoker < 15 years cessation. All participants reported demographic characteristics and smoking history and underwent a clinical assessment, spirometry, and thoracic LDCT screening. <bold>RESULTS:</bold> Between Feb/22 to Nov/23, we recruited 310 individuals; 277 underwent thoracic LDCT and 214 spirometry. We identified 30% participants with nodules. Seven participants required referral for lung biopsy; one was hamartoma, one was aspergillosis and 5 were lung cancer. We identified other CT abnormalities, such as coronary calcification (58%), calcification of other vessels (58%), emphysema (53%), bullae (33%), calcified granulomas (25%) and thickened bronchi wall (16%). The median of forced expiratory volume in the first second (FEV1) was 66.7±21.6% and forced volume capacity (FVC) was 79.4±17%. Fifty-four participants (17%) received a new diagnosis of COPD. The dyspnea index assessed by the Medical Research Council modified in COPD patients was 2.45±1.20. <bold>DISCUSSION:</bold> A comprehensive public lung cancer screening program in high-risk individuals is feasible and may help diagnosing other coexisting lung conditions.
Authors
- Érica Nishida Hasimoto (ORCID: https://orcid.org/0000-0002-5509-0862)
- Diane Rezende Batista (ORCID: https://orcid.org/0000-0001-7138-6105)
- Suzana Érico Tanni (ORCID: https://orcid.org/0000-0002-2587-2759)
- Luiz Machado (ORCID: https://orcid.org/0000-0002-5815-8340)
- Robson Prudente (ORCID: https://orcid.org/0000-0003-1175-1435)
- Kelly Mari Pires de Oliveira (ORCID: https://orcid.org/0000-0002-9897-7770)
- Vitor Nishiyama
- Juan P. Wisnivesky (ORCID: https://orcid.org/0000-0003-0299-4582)
- Estefânia Franco (ORCID: https://orcid.org/0000-0002-9917-0637)
- Aglaia Moreira Garcia Ximenes (ORCID: https://orcid.org/0000-0001-7677-8124)
- Letícia Ishimoto
- Tarcísio Reis
- I. Aguiar (ORCID: https://orcid.org/0000-0002-2230-1934)
- Ario Takeuchi (ORCID: https://orcid.org/0000-0002-5422-1672)
- Gustavo Augusto Ferreira Mota (ORCID: https://orcid.org/0000-0001-8103-3338)
- Felipe Silva (ORCID: https://orcid.org/0009-0003-8074-5781)
- Sérgio Conti Ribeiro (ORCID: https://orcid.org/0000-0001-6268-4979)
- Bruno S. Lima (ORCID: https://orcid.org/0000-0001-6230-8535)
- Gabriel Artiga
- Gabriel Reno
- Fabio Yamauchi
- Isadora Furlan
Institutions
- Mount Sinai Hospital (US)
- Medecell (Brazil) (BR)
- Universidade Estadual Paulista (Unesp) (BR)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Published
- 2024-09-14
- DOI
- https://doi.org/10.1183/13993003.congress-2024.pa4903
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.00